ACQUISITION OF ARGATROBAN BUSINESS IN EUROPE
2024-06-17
上市批准并购
SAINT-CLOUD, France, June 17, 2024 /PRNewswire/ --
Ethypharm has entered into an agreement with Mitsubishi Tanabe Pharma Corporation (MTPC) to acquire the selective antithrombin agent, Argatroban monohydrate (Argatra®, Arganova®, Novastan®, Exembol®), in Europe.
Ethypharm, known for its expertise in essential drugs for central nervous system diseases (including severe pain and addiction) and hospital injectables, aims to strengthen its established pharmaceutical business in Europe through internal development, licensing and acquisitions.
In Europe, MTPC first received approval for Argatroban in Sweden in 2004 and the product is currently available as a treatment for heparin-induced thrombocytopenia (HIT) type II in 13 countries, including Germany, the UK, France, Spain and Italy. Heparin induced thrombocytopenia (HIT) type II is a severe condition that carries the risk of fatal thromboembolic complications. Argatroban is an anticoagulant with a short half-life in the bloodstream that undergoes metabolism in the liver, making it suitable for patients post-surgery and those with kidney disease who may develop HIT type II.
Denis Delval, CEO of Ethypharm, said: "We are delighted to strengthen our portfolio of essential drugs and bring Argatroban to patients in Europe. Furthermore, we are proud to take over this product following its originator, the well-recognized Mitsubishi Tanabe Pharma Corporation."
About Ethypharm
Ethypharm is committed to improving patients' lives and making a positive impact on society and the environment.
Ethypharm has 1,700 employees dedicated to its various pharmaceutical activities, of which 1400 are in industrial operations.
The six production sites located in France, the UK, Spain, and China have expertise in injectables and complex oral solid forms.
With a global presence in 68 countries, the company markets its products directly in Europe and China, and has strategic partnerships in the EMEA, NA, LATAM and APAC markets.
Ethypharm works closely with the authorities and healthcare professionals to ensure that its medicines are used appropriately and that patients have access to them.
To find out more about Ethypharm, visit http://www.ethypharm.com
About Mitsubishi
In Europe, MTPC's subsidiary, Mitsubishi Tanabe Pharma Europe Ltd (hereinafter referred to as "MTPE," located in London, United Kingdom), and MTPE's subsidiary, Mitsubishi Tanabe Pharma GmbH (hereinafter referred to as "MTPD, located in Duesseldorf, Germany), have been actively involved in the marketing and sales of argatroban in United Kingdom and Germany, among other European countries, through their respective networks of partners.
Mitsubishi Tanabe Pharma Corporation (Chuo-ku, Osaka; Representative Director: Akihiro Tsujimura; hereinafter, "MTPC"), a member of the Mitsubishi Chemical Group remains committed to delivering pharmaceutical products to patients in Europe through MTPE and MTPD, including the continued supply of Radicava® (edaravone), treatment agent for amyotrophic lateral sclerosis, within its European operations, thereby making a meaningful contribution to those facing diseases in the region.
The company's six production sites are located in France, the UK, Spain and China.
Mitsubishi Tanabe Pharma Corporation (MTPC), a member of the Mitsubishi Chemical Group, is committed to delivering pharmaceutical products to patients in Europe through Mitsubishi Tanabe Pharma Europe Ltd (MTPE) and Mitsubishi Tanabe Pharma GmbH (MTPD). This includes the continued supply of Radicava® (edaravone), the treatment agent for amyotrophic lateral sclerosis, thereby making a meaningful contribution to those facing diseases in the region. In Europe, MTPE and its subsidiary MTPD have been actively involved in the marketing and sales of argatroban in the UK and Germany, among other European countries, through their respective networks of partners.
Logo - https://mma.prnewswire.com/media/2434581/Ethypharm_Logo.jpg
Media contact: Ethypharm: Avril Ponnelle, [email protected]
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
靶点
-来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。